Montes de Oca MB, Saviñón TJA

Language: Spanish
References: 17
Page: 107-110
PDF size: 63.18 Kb.

ABSTRACT

The introduction of the atypical antipsychotics (AA) have contributed significantly to our understanding of the different pahologic processes in the patients affected with schizophrenia. Up-today recently several comparatives articles had been published (olanzapine vs. risperidone, risperidone vs. clozapine and quetiapine vs. risperidone), another four had been completed (risperidone vs. olanzapine nor published due to discrepancies with data in some centers). Comparison studies are very complex but the design and data analysis is fundamental. There is not consensus as the best way to compare two drugs’ efficacy and each pharmaceutical laboratory follow their own rules. It is almost impossible to compare two drugs due to the inherited complexity in the presentations of this disorder. The attempts to compare the conventional antipsychotic only concluded that their efficacy is similar but the side effect profiles are basically what made them different.
We will review the data from these studies with the purpose to learn, as accurate as possible, the differences and the dimensions of schizophrenia that there is not superiority of one over the other when we extrapolate the data to a human been. The limitations are enormous and we will try to discuss the most prevalent as we go over the data. The study limits the comparison from two of the most popular AA currently available in the USA: olanzapine and risperidone.

REFERENCES

1. FDA data on the approval of the new atypical antipsychotics: risperidone, olanzapine. 1994-1996.

2. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment resistant schizophremia. Am J Psychiatry 1998; 155(7): 914-20.

3. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley Jr.C, Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharm 1997; 154: 1248-54.

4. Schooler N. Comments on article by Tran colleagues, “Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders”. J clin Psychopharmacol 1998; 18(2).

5. The collaborative working group on clinical trial evaluations. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. J Clin Psychiatry 1998; 59(12).

6. Conley, et al. Risperidone versus olanzapine in schizophrenia and schizoaffective disorder. ECNP, París, 1998.

7. Meitzer HY, McGurk SR. Atypicals on cognitive function. Schizophren Bull, in press.

8. Olanzapine versus risperidone versus haloperidol in treatment of schizophrenia, Schizophr Res. 1998; 29: 150-1.

9. Osser DN, Najarian D, Berman I. Olanzapine increases weight and triglyceride levels. APA meeting 1998. Toronto, Ontario, Canada.

10. McEvoy JP, Scheifler PL, Frances A. Eds. The expert concensus guideline series treatment of schizophrenia. J Clin Psychiatry 1999; 60(11).

11. Montes de Oca MB. Compilation of medication and possible CYP-450 drug-drug interactions. Presented in Grand Rounds conferences, NY 1999.

12. Titusvile NJ. Risperdal revised literature. Jansen Pharmaceutica 08560, USA. 1998.

13. Zyprexa revised literature. Eli Lilly Company, Indianapolis, IN 46285, USA. 1998.

14. Sthal SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. The Journal of Clinical Psychiatry 1999; 60(10).

15. Gelenberg AJ. Clozapine and pregnancy. Biological therapies in psychiatry Newsletter 1999; 6(22).

16. Chouinard G, Steinberg S. New clinical concept on neuroleptic induced supersensitivity disorders. In: Stancer HC, Garfinker PE, Rakoff VM, eds. Guidelines for use of psychotropics drugs. New York: Spectrum Publications; 1984, p. 205-27.

17. Peuskens J, ed. A literature review of Prolactin in schizophrenia. Clear perspectives, managing issues in schizophrenia. 1997; 1(3).